HIF1A and breast cancer: Interestingly, using breast cancer and colon adenocarcinoma mouse models, Bailey et al. recently demonstrated the efficacy of co-targeting HIF-1α and CTLA-4 in vivo, further highlighting a key role for HIF-1α in TILs [12].